This Week’s 6 Most Important Hedge Fund Moves
As we approach the nexus of third quarter 13F filings (next week), hedge funds have been very active in 13D and 13G land.
Posts Tagged ‘Peter Kolchinsky’
Ra Capital Boosts Exposure in Dynavax to 9.9%
Peter Kolchinsky's Ra Capital Management surged its position in Dynavax Technologies Corporation (NASDAQ:DVAX) to almost 26 million shares, a new filing with the SEC has revealed...
Peter Kolchinsky’s RA Capital Boosts Stake in Achillion to 21.2%
Peter Kolchinsky and his hedge fund, RA Capital Management, boosted their position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to 21.2%, a filing with the SEC showed.
A 6-Pack of Hedge Fund Moves to Take Note Of
There are over 8,000 hedge funds in existence today, but just an elite group is worth paying attention to.
Peter Kolchinsky, RA Capital Up Stake in Achillion Pharmaceuticals Even Higher
Peter Kolchinsky, Achillion Pharmaceuticals: This afternoon, Peter Kolchinsky and his hedge fund, RA Capital Management, strengthened their position in Achillion Pharmaceuticals...
Outerwall, Pandora & Achillion All Targets of Mega-Hedge Funds
Outerwall, Pandora, Achillion, hedge funds: It’s no secret that at Insider Monkey, we track hedge funds (discover why here).
Hedge Fund Week in Review: Activist Action
Here are the eleven most important moves made in the hedge fund world this week.
Bill Ackman reduced his Herbalife short significantly, replacing it with long-term put options.
Dan Loeb ups his activist campaign at Sotheby’s, snatching 9.
Peter Kolchinsky’s Biotech Fund Doubles Achillion Pharmaceuticals Position
RA Capital, Achillion Pharmaceuticals: In a 13G filing with the SEC, Peter Kolchinsky's RA Capital disclosed that it owns nearly 15% of infectious disease-focused biopharma player...
Biotech-Focused Hedge Fund is Bullish on ChemoCentryx Inc (CCXI)
Tracking the activity of hedge funds via their filings with the Securities and Exchange Commission is particularly crucial, since these filings reveal the latest moves made by...
Here is What Hedge Funds Think About Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
At the moment, there are tons of metrics shareholders can use to monitor their holdings. A couple of the most under-the-radar are hedge fund and insider trading sentiment.
Dyax Corp. (DYAX): Are Hedge Funds Right About This Stock?
Now, according to many of your fellow readers, hedge funds are viewed as delayed, old investment tools of a forgotten age.
Here is What Hedge Funds Think About Dynavax Technologies Corporation (DVAX)
If you were to ask many market players, hedge funds are seen as useless, outdated financial vehicles of a forgotten age.
Hedge Funds Are Buying ACADIA Pharmaceuticals Inc. (ACAD)
In the eyes of many of your fellow readers, hedge funds are viewed as overrated, outdated financial tools of a forgotten age.
Do Hedge Funds and Insiders Love Sequenom, Inc. (SQNM)?
If you were to ask many traders, hedge funds are seen as useless, outdated investment vehicles of a period lost to current times.
Is Achillion Pharmaceuticals, Inc. (ACHN) Going to Burn These Hedge Funds?
To the average investor, there are dozens of indicators market participants can use to analyze their holdings.
Do Hedge Funds and Insiders Love ArthroCare Corporation (ARTC)?
In the financial world, there are tons of metrics shareholders can use to analyze Mr. Market. A couple of the most innovative are hedge fund and insider trading sentiment.
OncoGenex Pharmaceuticals Inc (OGXI): Are Hedge Funds Right About This Stock?
To the average investor, there are many gauges shareholders can use to monitor stocks. Two of the most underrated are hedge fund and insider trading movement.
Sangamo Biosciences, Inc. (SGMO): Hedge Funds Are Bullish and Insiders Are Bearish, What Should You Do?
In the 21st century investor’s toolkit, there are a multitude of metrics market participants can use to track stocks.
Hedge Funds Are Crazy About Novavax, Inc. (NVAX)
To most shareholders, hedge funds are viewed as unimportant, old financial vehicles of years past.
Hedge Funds Are Buying ZIOPHARM Oncology Inc. (ZIOP)
In the eyes of most stock holders, hedge funds are seen as underperforming, outdated financial vehicles of years past.
This Metric Says You Are Smart to Sell Derma Sciences Inc (DSCI)
Derma Sciences Inc (NASDAQ:DSCI) was in 7 hedge funds' portfolio at the end of the first quarter of 2013. DSCI has seen a decrease in enthusiasm from smart money lately.
Hedge Funds Are Dumping Cytori Therapeutics Inc. (USA) (CYTX)
In the eyes of most stock holders, hedge funds are perceived as underperforming, old financial tools of the past.
Here is What Hedge Funds Think About Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) was in 11 hedge funds' portfolio at the end of March. INSM shareholders have witnessed an increase in enthusiasm from smart money of late.
Afternoon Aggregate News: Hedge Fund Net Inflows, Oshkosh Blast Icahn.
Hedge funds ended the year on a high note, with positive net inflows of 1.55% in December, according to the GlobeOp Capital Movement Index.
